Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric:MetBio-GC

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This prospective clinical observational study aims to construct a metabolite database specifically for gastric cancer patients using metabolomics technology. It seeks to develop and validate metabolic biomarkers for early diagnosis, prognosis, and prediction of recurrence and metastasis in gastric cancer, thereby a establishing safe, convenient, and highly sensitive method for early screening and prognostic prediction.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• \*\*Healthy Controls:\*\*

∙ Age \> 18 years;

‣ Signed informed consent and willingness to participate in the project.

• \*\*Gastric Cancer:\*\*

⁃ Age ≥ 18 years;

⁃ Performance status (ECOG) score ≤ 1;

⁃ Histopathologically confirmed gastric adenocarcinoma;

⁃ No family history of hereditary cancer;

⁃ No prior anti-tumor treatment;

⁃ Availability of primary tumor tissue from surgery or biopsy that meets submission requirements;

⁃ Availability of peripheral blood samples that meet submission requirements;

⁃ Willingness and ability to sign the informed consent form to participate in the study.

Locations
Other Locations
China
Ruijin hospital Shanghai Jiaotong University, School of Medicine , Shanghai, Shanghai 200025
RECRUITING
Shanghai
Contact Information
Primary
Jing Sun
sj117788@rjh.com.cn
+86-13524284622
Time Frame
Start Date: 2025-06-15
Estimated Completion Date: 2030-07-01
Participants
Target number of participants: 250
Treatments
Baseline
This group recruits healthy individuals which is intended to establish a metabolic biomarker baseline
GC
Gastric cancer group, which is study of interest
Related Therapeutic Areas
Sponsors
Leads: Shanghai Minimally Invasive Surgery Center

This content was sourced from clinicaltrials.gov